Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Dong Mee Lee"'
Autor:
Ki-Jae Park, Sung-Hyun Kim, Suee Lee, Sung Yong Oh, Jong-Hoon Lee, Dong Mee Lee, Mee-Sook Roh, Hyo-Jin Kim, Hongjo Choi, Hyukchan Kwon, Dae-Cheol Kim
Publikováno v:
American Journal of Clinical Oncology. 32:38-43
Background: The aim of this study was to determine whether the expression of the excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS) and glutathione S-transferase IT (GSTπ) predict clinical outcome in patients with advanced colo
Autor:
Hyuk Chan Kwon, Jin Seok Jang, Dong Mee Lee, Min Chan Kim, Hyun-Seung Yoo, Hyo-Jin Kim, Suee Lee, Sung-Hyun Kim, Jin Sook Jeong, Sung Yong Oh
Publikováno v:
Japanese Journal of Clinical Oncology. 37:930-935
Background: Clinical studies regarding chemotherapy for gastric cancer patients with malignant ascites have been classically rather limited in scope, largely because peritoneal seeding produces no measurable lesions, and patients generally exhibited
Autor:
Sunghyun Kim, Byung Geun Kim, Dong Mee Lee, Seong-Geun Kim, Hyukchan Kwon, Jin Seok Jang, Sung Yong Oh, Hyo-Jin Kim, Do-Kyong Kim, Min Chan Kim, Suee Lee
Publikováno v:
American journal of clinical oncology. 33(3)
Background: To determine the activity and toxicities of a low-dose leucovorin plus 5-fluorouracil (5-FU) regimen, combined with irinotecan and administered every 2 weeks (modified FOLFIRI), as a first-line therapy for patients with advanced gastric c
Autor:
Dong Mee Lee, Ha Yeon Kim, Sunghyun Kim, Suee Lee, Sook Hee Hong, Hyo-Jin Kim, Jin Han Yoon, Sung Yong Oh, Hyukchan Kwon
Publikováno v:
Acta haematologica. 120(3)
Primary penile lymphoma is rarely observed in cases of extranodal malignant lymphoma. Owing principally to its rarity, no definite treatment modality has been established. We report the case of a 42-year-old man who presented with hematuria and a pai
Autor:
Hyun-Won Kim, D. S. Heo, Jung-Joo Choi, J.W. Kim, S-W. Kim, D-Y Kim, Belong Cho, Dong Mee Lee, Mi Ran Jung, Sunmi Kang
Publikováno v:
Journal of Clinical Oncology. 28:7547-7547
7547 Background: Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities. Given their inhibitory target prof...
Autor:
Suee Lee, Hyo-Jin Kim, Jin-Yeong Han, Kyung-Eun Kim, Sung-Hyun Kim, Jung Hwan Kim, Sung Yong Oh, Dong Mee Lee, Hyuk-Chan Kwon
Publikováno v:
The Korean Journal of Hematology. 44:14
Background: For patients with multiple myeloma (MM), different strategies are used to detect chromosomal abnormalities (CA). There have been a few studies that have directly compared FISH with conventional cytogenetics (CC) for the detection of CA. I
Autor:
Suee Lee, Sung Yong Oh, Dong Mee Lee, Kyu-Yeol Lee, Kyeong Hee Kim, Jong-Hwan Lee, Sung Hyun Kim, Hyo-Jin Kim, Joo In Park, Jin-Yeong Han, H. Kwon
Publikováno v:
Blood. 112:4068-4068
Background: Patients may be unwilling to accept blood products for religious reasons – Jehovah’s Witnesses (JW). Because of its minority, as well as JW patients, physicians have a lot of difficulty and anxiety to treatment. Furthermore, sometimes
Autor:
Suee Lee, Myung Hwan Rho, Sung Yong Oh, Young Hoon Kim, Jaehyuk Choi, Jung Hwan Kim, Jae Hoon Lee, Dong Mee Lee, Mee-Sook Rho, Hyo-Jin Kim, Sung-Hyun Kim, Hyuk-Chan Kwon
Publikováno v:
Cancer Research and Treatment. 40:22
Gemcitabine is the most active agent to treat unresectable pancreatic cancer. The superiority of combining other drugs with cisplatin is still controversial; therefore, we performed a retrospective analysis of gemcitabine versus gemcitabine combined
Autor:
Hyuk-Chan Kwon, Dong Mee Lee, Sung-Hyun Kim, Suee Lee, Hyun Ah Yoon, Hyo-Jin Kim, Sung Yong Oh, Soo-Keol Lee
Publikováno v:
The Korean Journal of Hematology. 42:423
Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
Autor:
Ji-Hoon Jo, Young-Rak Cho, Bong-Gun Seo, Hyo-Jin Kim, Dong-Mee Lee, Jae-Seok Kim, Hyuk-Chan Kwon, Sunghwan Suh, Sung-Hyun Kim
Publikováno v:
Cancer Research and Treatment. 37:279
Purpose To determine the activity and the toxicity associated with a low dose regimen of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every two weeks (modified FOLFOX 4) as a salvage therapy for advanced gastric cancer patient